tlooto

A Comparative Clinical Study of 0.50% Versus 0.75% Pilocarpine Eye Drops for Improving Visual Performance in Presbyopia

Dan Fu, Tian Han, Qiyu Wang, Jingbin Geng, Shulong Gu, Yuan Ji, Taomin Huang, Xingtao Zhou, Ye Xu

2026.3.10Ophthalmic and Physiological Optics

Paper details

Journal
Ophthalmic and Physiological Optics
Published
2026.3.10
Citations
0
References
28
Fields
Medicine

Abstract

Objective To compare the efficacy and safety of 0.50% and 0.75% pilocarpine ophthalmic solutions for treating presbyopia. Methods In this prospective study, 22 presbyopic subjects (44 eyes) were assigned to use 0.50% or 0.75% pilocarpine bilaterally, once daily for 2 weeks. Primary outcomes included distance-corrected intermediate visual acuity (DCIVA) at 66 cm and distance-corrected near visual acuity (DCNVA) at 40 cm under photopic and mesopic conditions, pupil size, refractive error, intraocular pressure (IOP) and patient-reported adverse events. Assessments were conducted at baseline, day 1 (after 1 and 6 h) and week 2 (after 1 h). Results No serious adverse events occurred. Neither formulation affected IOP or refractive error significantly. Pupil constriction was greater in the 0.75% group than the 0.50% group (2.8 ± 1.1 vs. 2.0 ± 0.8 mm, p = 0.02). After 2 weeks, the gain in photopic DCNVA was 0.18 logMAR for both concentrations (p = 0.70). The respective gain in visual acuity measures for the 0.75% and 0.50% groups was: mesopic DCNVA, 0.14 and 0.19 logMAR (p = 0.25); photopic DCIVA, 0.14 and 0.09 logMAR (p = 0.02); mesopic DCIVA, 0.12 and 0.10 logMAR (p = 0.18). Conclusion Both 0.50% and 0.75% pilocarpine improved visual performance in presbyopia significantly, suggesting it is a promising treatment option. Clinical trial registration Chinese Clinical Trial Registry (ChiCTR), 2023/3/2, No.ChiCTR2300068971.

Citation format

FU, Dan, et al. A comparative clinical study of 0.50% versus 0.75% pilocarpine eye drops for improving visual performance in presbyopia. Ophthalmic and Physiological Optics, 2026, 46(2): 331–336.